Evidence map›Paper›PMID 39574510›Full record

ArticleFrontiers in neurology2024

A comparison of natalizumab's effects on SDMT between pediatric-onset and adult-onset multiple sclerosis patients.

Marco Puthenparampil, Graziana Scialpi, Marta Gaggiola, Giovanni Zanotelli, Alessandro Miscioscia, Angela Berardi, Alice Riccardi, Margherita Nosadini, Stefano Sartori, Paola Perini and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marco PuthenparampilDepartment of Neurosciences, University of Padua, Padova, Italy.
Graziana ScialpiDepartment of Neurosciences, University of Padua, Padova, Italy.
Marta GaggiolaDepartment of Neurosciences, University of Padua, Padova, Italy.
Giovanni ZanotelliDepartment of Neurosciences, University of Padua, Padova, Italy.
Alessandro MisciosciaDepartment of Neurosciences, University of Padua, Padova, Italy.
Angela BerardiDepartment of Neurosciences, University of Padua, Padova, Italy.
Alice RiccardiDepartment of Neurosciences, University of Padua, Padova, Italy.
Margherita NosadiniPaediatric Neurology and Neurophysiology Unit, Department of Women's and Children's Health, University Hospital of Padova, Padova, Italy.
Stefano SartoriPaediatric Neurology and Neurophysiology Unit, Department of Women's and Children's Health, University Hospital of Padova, Padova, Italy.
Paola PeriniMultiple Sclerosis Centre, Azienda Ospedaliera di Padova, Padova, Italy.
Francesca RinaldiMultiple Sclerosis Centre, Azienda Ospedaliera di Padova, Padova, Italy.
Paolo GalloDepartment of Neurosciences, University of Padua, Padova, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pediatric-onset multiple sclerosis (POMS) patients often exhibit a wide range of cognitive deficits. Therefore, therapeutic approaches should aim not only to prevent cognitive decline but also to promote cognitive improvement. Objective: This study aimed to explore the effects of natalizumab (NTZ) on cognitive function, as measured by the Symbol Digit Modalities Test (SDMT), in both POMS and adult-onset multiple sclerosis (AOMS) patients. Method: A total of 63 patients (34 AOMS and 29 POMS) were enrolled in this retrospective, single-center study. Patients were clinically and radiologically assessed every 6 months, and they completed the SDMT at baseline and after at least 24 months of follow-up. SDMT values were reported as corrected values (cSDMT) and z-scores (zSDMT). Annualized cSDMT and zSDMT scores were calculated by dividing the change in scores by the length of the follow-up period (expressed in years). Results: Both POMS and AOMS groups showed improvement in annualized cSDMT and zSDMT scores, but the improvement was significantly greater in the POMS group compared to the AOMS group (+3.85 ± 4.32 vs. +1.76 ± 2.80, Conclusion: The favorable clinical, radiological, and neuropsychological outcomes observed in this study support the use of natalizumab as a viable treatment option in POMS.

Indexed as

multiple sclerosisnatalizumabneuropsychological outcomepediatric-onset multiple sclerosisSymbol Digit Modalities Test

Identifiers

PMID39574510
PMCPMC11579921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.